Prescription medicine
Flunisolide First approved as Nasalide
Flunisolide (Nasalide) is a prescription medicine with an FDA approval on record since 1981. FDA's NDC Directory lists it from 3 generic labelers, and pharmacies paid $1.99 per mL (Flunisolide 0.025% spray) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the flunisolide FDA label on DailyMed (effective January 16, 2025, Bausch & Lomb Incorporated); the NDA 18148 record on Drugs@FDA; every flunisolide label on DailyMed.
Highlights of the record
FDA label of January 16, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageFlunisolide Nasal Solution is indicated for the treatment of the nasal symptoms of seasonal or perennial rhinitis.
Forms and strengths
- 0.25 mg/ml
Solution.
On the market
- Earliest approval on file
- September 24, 1981 Nasalide, Ivax Res; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 4 first February 20, 2002; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 3 of which 3 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $1.99 per mL Flunisolide 0.025% spray
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2022 0 Class I among all firms' recalls; latest September 30, 2022
- FAERS reports
- 1,488 through July 30, 2026
What is flunisolide used for?
From the label: indications and usageFlunisolide Nasal Solution is indicated for the treatment of the nasal symptoms of seasonal or perennial rhinitis. Flunisolide Nasal Solution should not be used in the presence of untreated localized infection involving nasal mucosa.
FDA pharmacologic class: Corticosteroid.
Source: FDA drug label (Flunisolide), Bausch & Lomb Incorporated, effective January 16, 2025 (SPL set 7c72c954-3758-40c3-9977-d03b25d71e0a), via openFDA; the full label on DailyMed
Is there a generic for flunisolide (Nasalide)?
The FDA approved the first generic flunisolide on February 20, 2002. 4 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists flunisolide from 3 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1981 earliest approval on file
- 2002 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for flunisolide (Nasalide)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $1.99 per mL (Flunisolide 0.025% spray), up 15% from $1.72 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Flunisolide 0.025% spray (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Flunisolide 0.025% spray | Generic | $1.99 per mL | n/a | +15% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has flunisolide been recalled?
The FDA's Enforcement Report lists 1 recall naming flunisolide since 2022: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| September 30, 2022 | Class II | Ingenus Pharmaceuticals Llc | Out of specification for related substances (impurities). |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the flunisolide label say about other medicines?
The flunisolide label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Prednisone | warnings | The use of flunisolide with alternate-day prednisone systemic treatment could increase the likelihood of HPA suppression compared to a therapeutic dose of either one alone. |
Source: FDA drug label (Flunisolide), Bausch & Lomb Incorporated, effective January 16, 2025 (SPL set 7c72c954-3758-40c3-9977-d03b25d71e0a), via openFDA; the full label on DailyMed
What do FAERS reports show for flunisolide?
The FDA Adverse Event Reporting System holds 1,488 reports that list flunisolide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 100 are coded as a death and 584 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other corticosteroids
- the pharmacologic class, with prices and generics
- Flunisolide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other